Display options
Cite
Barr C. The future research agenda. A view from the pharmaceutical industry. Pharmacoeconomics. 1994;6:61-2doi: 10.2165/00019053-199400061-00014.
Barr, C. (1994). The future research agenda. A view from the pharmaceutical industry. PharmacoEconomics, 661-2. https://doi.org/10.2165/00019053-199400061-00014
Barr, C. "The future research agenda. A view from the pharmaceutical industry." PharmacoEconomics vol. 6 (1994): 61-2. doi: https://doi.org/10.2165/00019053-199400061-00014
Barr C. The future research agenda. A view from the pharmaceutical industry. Pharmacoeconomics. 1994;6:61-2. doi: 10.2165/00019053-199400061-00014. PMID: 10155587.
Copy Download .nbib Format: NLM
Share it on

Pharmacoeconomics. 1994;6:61-2. doi: 10.2165/00019053-199400061-00014.

The future research agenda. A view from the pharmaceutical industry.

PharmacoEconomics

C Barr

Affiliations

  1. International Pharmaceuticals Group, Pfizer Inc, New York, USA.

PMID: 10155587 DOI: 10.2165/00019053-199400061-00014

Abstract

As a responsible partner in healthcare systems, the pharmaceutical industry hopes to see a research agenda on pharmaceutical issues that will provide more information on trends in healthcare reform affecting medicines. Urgent questions include whether some forms of cost containment are harming innovation and the quality of care, and what constructive alternatives to policies such as reference pricing can the industry offer?

References

  1. Pharmacoeconomics. 1994;6 Suppl 1:39-41 - PubMed
  2. Pharmacoeconomics. 1994;6 Suppl 1:3-10 - PubMed

MeSH terms

Publication Types

LinkOut - more resources